Some Pediatric Patients With Wilms' Tumor Can Avoid Doxorubicin
the ONA take:
According to a new study published in the journal The Lancet, researchers have found that children with Wilm's tumor who are at low risk for relapse can be given less intensive treatment by omitting doxorubicin from the treatment regimen.
For the 10-year trial, researchers followed 583 pediatric patients with stage II or III Wilm's tumor who were at intermediate risk for disease relapse. Results demonstrated that 96.5% of patients whose treatment regimen contained doxorubicin survived for 5 or more years versus 95.8% of those who did not receive the cardiotoxic drug. Researchers found that those who did not receive doxorubicin and relapsed could be successfully re-treated.
"Thanks to the results of this trial fewer children with this disease will have to have treatment that could cause them lifelong side effects without much benefit," lead author Professor Kathy Pritchard-Jones, a researcher at the Institute of Child Health, University College London and consultant oncologist at Great Ormond Street Hospital in London said.
Children with Wilm's tumor who are at low risk for relapse can be given less intensive treatment by omitting doxorubicin from the treatment regimen.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|